Here is some recent news about Aiforia. 
Fimlab Laboratories Ltd, Finland’s largest healthcare technology company, has selected Aiforia Technologies Plc as the provider for breast and prostate cancer diagnostics solutions. The value of the first order is approximately EUR 300,000 for the first year, which is some 7% of our 2024 revenue forecast. The order and the concrete launch of the collaboration again support Aiforia’s strong growth prospects.